Contact
Please use this form to send email to PR contact of this press release:
Opinion/decision on a Paediatric investigation plan (PIP): Anti-TGFbeta fully human monoclonal antibody (NIS793), decision type: , therapeutic area: , PIP number: P/0207/2022
TO: